aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma announced subgroup analysis from their Phase 3 EFZO-FIT study showing clinically meaningful improvements in lung function and multiple patient-reported outcomes in pulmonary sarcoidosis patients with restrictive lung disease treated with 5.0 mg/kg efzofitimod. The company submitted a protocol to the FDA for a targeted Phase 3 study focu…